Clinical significance of the BRAF(V600E) mutation in multifocal papillary thyroid carcinoma in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Hwa Young | - |
dc.contributor.author | Chung, Yun Jae | - |
dc.contributor.author | Kim, Byung Seup | - |
dc.contributor.author | Kang, Kyung Ho | - |
dc.contributor.author | Seok, Ju Won | - |
dc.contributor.author | Kim, Hee Sung | - |
dc.contributor.author | Park, Sung Jun | - |
dc.contributor.author | Cho, Bo Youn | - |
dc.date.available | 2019-03-08T22:00:19Z | - |
dc.date.issued | 2014-04 | - |
dc.identifier.issn | 0039-6060 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/12345 | - |
dc.description.abstract | Background. We examined the fequency of the BRAF(V600E) mutation and compared the clinicopathologic features based on the BRAF(V600E) mutation status in multifocal papillary thyroid carcinoma (PTC). Methods. A total 85 patients who were diagnosed with multifocal PTC were enrolled. We confirmed the status of the BRAF(V600E) mutation in each tumor focus by the real-time polymerase chain reaction technique. Results. Among the 85 patients, 49 (57.6%), 34 (40.0%), and 2 (2.4%) patients were determined to have all BRAF(V600E)-positive, mixed BRAF(V600E), and all BRAF(V600E)-negative in their tumor foci, respectively. When we compared clinicopathologic features according to the BRAF(V600E) mutation status of the dominant tumor, the BRAF(V600E)-positive group (n = 70) showed more extrathyroidal invasion in the dominant tumor (32.9% vs 6.7%, P = .041) and more lymph node metastasis (67.2% vs 40.0%, P =.049) than the BRAF(V600E)-negative group (n = 15). Considering all tumor foci, the all BRAF(V600E) mutation group exhibited a younger population (P = .039), showed increased extrathyroidal invasion. (38.8% vs 14.7%, P = .017) and lymph node metastasis (71.4% vs 48.4%, P = .038), and received more radioactive iodine therapy (79.2% vs 52.9%, P = .012) than the mixed BRAF(V600E) mutation group. A larger tumor size and heavier preoperative bogy weight was positively correlated with the relative expression of BRAF(V600E) mutation calculated by 2(-Delta Delta Ct) method. Conclusion. Most of the Korean patients with multifocal PTC had the BRAF(V600E) mutation in one or more tumor foci, and all BRAF(V600E)-positive multifocal PTC showed more aggressive features. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MOSBY-ELSEVIER | - |
dc.title | Clinical significance of the BRAF(V600E) mutation in multifocal papillary thyroid carcinoma in Korea | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.surg.2013.12.025 | - |
dc.identifier.bibliographicCitation | SURGERY, v.155, no.4, pp 689 - 695 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000333661300014 | - |
dc.identifier.scopusid | 2-s2.0-84897036017 | - |
dc.citation.endPage | 695 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 689 | - |
dc.citation.title | SURGERY | - |
dc.citation.volume | 155 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordPlus | BRAF V600E MUTATION | - |
dc.subject.keywordPlus | DISTINCT TUMOR FOCI | - |
dc.subject.keywordPlus | CLONAL ORIGIN | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | PREDICTS | - |
dc.subject.keywordPlus | WEIGHT | - |
dc.subject.keywordPlus | RISK | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.